Formulary updates

August 2017

Fiasp® insulin aspart 100 units per 1ml, 10ml vials, 3ml cartridges, and 3ml FlexTouch® prefilled devices have been added into the formulary for use in patients aged 18 years and over. Please see the formulary for further information.

Carbocisteine oral liquid 250mg/5ml has been removed from the formulary. Carbocisteine sachets 750mg/10ml sugar free oral solution remains in the formulary. Please see the formulary for more information.

Catheter patency (maintenance) solutions: The guidance has been refreshed to offer clarity on when solutions may be recommended, and provide guidance towards more cost-efficient product usage. OptiFlo® S, OptiFlo® G, and OptiFlo® R saline catheter patency solutions have been removed from the formulary. Please see the formulary for up to date guidance and further information.

Emergency contraception: The guidance for emergency contraception has been reviewed and updated, following new advice from The Faculty of Sexual and Reproductive Healthcare (FSRH) Please see the formulary for up to date guidance. Ulipristal acetate tablets 30mg has been reclassified as green first line preferred treatment of emergency contraception, and Levonorgestrel tablets 1.5mg has been reclassified as blue second line treatment, following the update. Please see the formulary for further information.

Management of epilepsy: The guidance has been refreshed and expanded to emphasise MHRA Drug Safety Updates. Please see the formulary for up to date guidance and further information.

July 2017

Lyrica® has been removed as the preferred brand of pregabalin, generic prescribing is now recommended. Please see the formulary for further information.

Soltel® aerosol inhalation 25micrograms/ metered inhalation has been added into the formulary as the preferred brand of salmeterol inhaler. Soltel® is contraindicated in patients who have peanut and soya allergies. Please see the formulary for further information.

Lecicarbon A suppositories have been added into the formulary for the management of chronic constipation, following a commissioning decision from the Clinical Policy Committee. Please see the formulary for further information.

Ralvo® medicated plasters 700mg have been added as a preferred brand of lidocaine plasters, for the treatment of post-herpetic neuralgia, and should only be used following initiation by the Pain Clinic. Please see the formulary for further information.

Sodium oxybate oral solution 500mg in 1ml has been added into the formulary for the management of narcolepsy with cataplexy in adults aged 19 years and older, in line with specific criteria, following a commissioning decision from the Clinical Policy Committee. Please see the formulary for further information.

June 2017

Prednisolone 10mg/ml oral solution 30ml bottle has been added into the formulary for patients unable to use standard tablets when total treatment exceeds 150mg. Please see the formulary for further information.

Vensir® XL and Venlablue® XL have been removed as the preferred brands of venlafaxine m/r capsules. Please see the formulary for more information.

Glucodrate® oral powder sachets have been added into the formulary only for patients with short bowel syndrome who are unable to tolerate St Mark's Electrolyte Solution.

NovoRapid PumpCart® insulin aspart 100 units per 1ml, 1.6ml cartridges has been added into the formulary. Please see the formulary for further information.

Diagnostic and monitoring devices for diabetes mellitus: was reviewed and has been refreshed and expanded to include additional information from NICE guideline NG17 (Type 1 diabetes in adults: diagnosis and management). Please see the formulary for further information.

Continence (Chapter 18): has been reviewed following consultation with specialists and the chapter has been refreshed, updated with relevant products, advice, and quick guides. Please see the formulary for further information.

 

Home > Formulary > Updates > Recent Updates

 

  • First line
  • Second line
  • Specialist
  • Hospital